...
首页> 外文期刊>癌と化学療法 >A case of multi-drug resistant recurrent breast cancer with multiple bone metastasis responding to TS-1 and trastuzumab
【24h】

A case of multi-drug resistant recurrent breast cancer with multiple bone metastasis responding to TS-1 and trastuzumab

机译:具有多重骨转移的多药物抗性乳腺癌的情况,响应TS-1和曲妥珠单抗

获取原文
获取原文并翻译 | 示例

摘要

We experienced a case of multi-drug resistant recurrent breast cancer with multiple bone metastases achieving a significant improvement by TS-1 and trastuzumab. The prior treatments including taxane or vinorelbine and trastuzumab were changed in the regimen to TS-1 and trastuzumab because of the progressive disease. TS-1 was administered orally at 100 mg/day everyday for 2 weeks, followed by a 1-week rest interval as 1 cycle, and trastuzumab was injected at 2 mg/kg/week for 4 weeks, followed by a 1-week rest interval as 1 cycle. After 3 cycles of the treatment, the level of tumor markers and tumor sizes of bone metastases became reduced. In conclusion, the combination treatment of TS-1 and trastuzumab is thought to be effective for multi-drug resistant recurrent breast cancer.
机译:我们经历了多种耐药性复发性乳腺癌的情况,具有多种骨转移,通过TS-1和TRASTUZIMAB实现显着改善。 由于进展性疾病,在制造方案中,包括紫杉烷或血管素和曲妥珠单抗的现有治疗方法发生在TS-1和Trastuzumab中。 每天在100mg /天口服施用Ts-1 2周,然后将1周的休息间隔为1个循环,并且曲妥珠单抗注射在2mg / kg /周的4周,然后休息1周 间隔为1个循环。 在治疗3周期后,肿瘤标志物和肿瘤尺寸的水平降低。 总之,TS-1和Trastuzumab的组合治疗被认为是对多药物抗性复发性乳腺癌有效的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号